Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAILBLAZER-ALZ 5: Donanemab in Early Symptomatic Alzheimer’s Disease
2025-522340-40-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Donanemab with Placebo (2 arms). Primary endpoint: Change from Baseline on the Integrated Alzheimer’s Disease Rating Scale (iADRS). Planned start Oct 2025; status: authorised.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2025-522340-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522340-40-00.